Literature DB >> 28554413

The Nonmotor Features of Parkinson's Disease.

Nataliya Titova1, Mubasher A Qamar2, K Ray Chaudhuri3.   

Abstract

Nonmotor symptoms (NMS) of Parkinson's disease (PD) were recognized by the great James Parkinson himself who mentioned symptoms such as sleep dysfunction, delirium, dementia, and dysautonomia, in his seminal 1817 essay, "An Essay on the Shaking Palsy" (Parkinson, 1817). In spite of the key impact of PD NMS on quality of life, there was little holistic research and awareness till the validation and use of comprehensive tools such as the NMS questionnaire, scale, and the revised version of the unified PD rating scale. Research studies using these tools highlighted the key impact of the burden of NMS on quality of life of PD patients and the need for NMS to be routinely assessed in clinic. We now define PD as a motor and nonmotor disorder, and the natural history includes a long prodromal phase of PD dominated by a range of NMS. The prodromal phase is the subject of much research particularly in relation to neuroprotection and identifying subjects at risk. Use of NMS tools has also validated burden grading of NMS with cutoff values, which can be used as outcome measure in clinical trials. Finally, the complex multineurotransmitter dysfunction that is seen in PD has been shown to manifest clinically as nonmotor subtypes. Recognition of such subtypes is likely to lead to the emergence of personalized and precision medicine in PD.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Classification; Nonmotor subtypes; Nonmotor symptoms burden; Nonmotor symptoms questionnaire; Nonmotor symptoms scale; Parkinson's disease; Quality of life

Mesh:

Year:  2017        PMID: 28554413     DOI: 10.1016/bs.irn.2017.02.016

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  17 in total

Review 1.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

2.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

Review 3.  Parkinson's disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair.

Authors:  Bianca Marchetti; Cataldo Tirolo; Francesca L'Episcopo; Salvatore Caniglia; Nunzio Testa; Jayden A Smith; Stefano Pluchino; Maria F Serapide
Journal:  Aging Cell       Date:  2020-02-12       Impact factor: 9.304

Review 4.  Nucleic Acid-Based Therapeutics for Parkinson's Disease.

Authors:  Masayuki Nakamori; Eunsung Junn; Hideki Mochizuki; M Maral Mouradian
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 5.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 6.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

7.  Touchscreen typing-pattern analysis for detecting fine motor skills decline in early-stage Parkinson's disease.

Authors:  Dimitrios Iakovakis; Stelios Hadjidimitriou; Vasileios Charisis; Sevasti Bostantzopoulou; Zoe Katsarou; Leontios J Hadjileontiadis
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

Review 8.  Amyloid-β and Parkinson's disease.

Authors:  Ee Wei Lim; Dag Aarsland; Dominic Ffytche; Raquel Natalia Taddei; Daniel J van Wamelen; Yi-Min Wan; Eng King Tan; Kallol Ray Chaudhuri
Journal:  J Neurol       Date:  2018-10-30       Impact factor: 4.849

Review 9.  Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease.

Authors:  Daniel J van Wamelen; Sotirios Grigoriou; K Ray Chaudhuri; Per Odin
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

Review 10.  Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based Case-Control Study.

Authors:  Roberto Cilia; Salvatore Bonvegna; Giulia Straccia; Nico Golfrè Andreasi; Antonio E Elia; Luigi M Romito; Grazia Devigili; Emanuele Cereda; Roberto Eleopra
Journal:  Mov Disord       Date:  2020-06-11       Impact factor: 9.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.